+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of CLS2901C human allogenic chondrocyte sheets combined with proximal tibial osteotomy compared to osteotomy alone in patients with osteoarthritis of the knee OAK. This phase III study focuses on patients aged 20 to 79 years diagnosed with OAK, classified by specific X-ray criteria. The purpose is to understand how this new cellular therapy may impact knee function and symptoms over time. The study involves two groups one receiving osteotomy surgery alone and the other receiving osteotomy combined with CLS2901C chondrocyte sheets applied to the knee. The chondrocyte sheets are made by culturing cartilage cells derived from patients with polydactyly. The evaluation period for each group lasts about 14.5 months, including 52 weeks of active assessment followed by up to 5 years of additional observation for those available to continue. Participants will undergo various assessments including knee function measured by the KOOS 4 score over 52 weeks. Safety is monitored through adverse event rates and product malfunctions. Researchers will also continue to observe patients for up to 5 years after receiving the chondrocyte sheets to evaluate long-term effects. The overall study duration spans from initial treatment through extended follow-up to fully understand treatment outcomes and safety.

Age: 20Years - 79YearsAll GendersPhase 3
6 locations
C

Actively Recruiting

This research investigates the effects of hypothermia versus normothermia on patients who have undergone extracorporeal cardiopulmonary resuscitation ECPR following out-of-hospital cardiac arrest OHCA. The trial aims to compare mortality risks, neurological outcomes, and adverse events between these two temperature management strategies. The study addresses uncertainties regarding the best temperature control after ECPR, which is a resuscitation method using ECMO to support heart and lung function during cardiac arrest. Participants receive either hypothermia treatment, where their body temperature is cooled to 33-34C using ECMO with a heat exchanger, or normothermia treatment, where the temperature is maintained at 36C. After reaching the target temperature, it is maintained for 24 hours, followed by a 24-hour rewarming period to 36-37.5C, which is then sustained until ECMO ends or for 24 hours post-rewarming. Additional treatments like sedation, muscle relaxants, antipyretics, and circulatory support may be used as needed. During the trial, participants are closely monitored for survival at discharge about 25 days, neurological function using cerebral performance categories, and adverse events during their intensive care stay approximately two weeks. Follow-up assessments occur at 30 days, 90 days, and one year after admission. The study tracks these outcomes to evaluate which temperature management approach might better support recovery after ECPR in OHCA patients.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
29 locations
A

Actively Recruiting

Researchers are evaluating the efficacy and safety of deuruxolitinib in Japanese adults aged 18 to 65 who have severe alopecia areata with at least 50% scalp hair loss. This Phase 3 study includes a double-blind, randomized, placebo-controlled treatment period followed by an open-label extension. The trial aims to assess how well deuruxolitinib works and its safety in this population. Participants will be randomly assigned to receive either deuruxolitinib 8 mg orally twice daily or a matching placebo during the initial 24-week double-blind treatment phase. Following this, all participants will enter a 52-week open-label extension where they will receive deuruxolitinib 8 mg twice daily. This design allows comparison between the drug and placebo initially, then all participants receive the active drug. Throughout the study, participants will undergo regular assessments including measuring scalp hair loss using the Severity of Alopecia Tool SALT score at various weeks. Patient satisfaction and clinician-reported outcomes will also be evaluated. Safety monitoring will include tests for infections and organ function. The primary outcome is the percentage of subjects achieving a SALT score of 20 or less at Week 24. Overall participation lasts up to 76 weeks including both treatment periods.

Age: 18Years - 65YearsAll GendersPhase 3
18 locations